SCHEMBL3301850

SCHEMBL3301850

Nc1ncnn2c(C3CCC(CN4CCCC4)CC3)nc(-c3cccc(OCc4ccccc4)c3)c12

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 14/20 0.76
ROCK2 O75116 1/20 0.65
PRKD3 O94806 1/20 0.65
INSR P06213 1/20 0.65
LYN P07948 1/20 0.65
RET P07949 1/20 0.65
FGFR1 P11362 1/20 0.65
RPS6KB1 P23443 1/20 0.65
FLT4 P35916 1/20 0.65
FLT3 P36888 1/20 0.65
FRK P42685 1/20 0.65
STK3 Q13188 1/20 0.65
ROCK1 Q13464 1/20 0.65
PTK6 Q13882 1/20 0.65
ERBB4 Q15303 1/20 0.65
NTRK3 Q16288 1/20 0.65
AURKB Q96GD4 1/20 0.65
PRKD2 Q9BZL6 1/20 0.65
MKNK2 Q9HBH9 1/20 0.65
MAP4K5 Q9Y4K4 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3297994 0.99 IGF1R (0.75) IGF1RROCK2PRKD3INSRLYN
SCHEMBL3298071 0.98 IGF1R (0.76) IGF1RROCK2PRKD3INSRLYN
SCHEMBL3298049 0.95 IGF1R (0.69) IGF1RROCK2PRKD3INSRLYN
SCHEMBL3298032 0.94 IGF1R (0.68) IGF1RROCK2PRKD3INSRLYN
SCHEMBL3294619 0.94 IGF1R (0.69) IGF1RROCK2PRKD3INSRLYN
SCHEMBL3294653 0.92 IGF1R (0.76) IGF1RROCK2PRKD3INSRLYN
SCHEMBL3303492 0.91 IGF1R (0.73) IGF1RROCK2PRKD3INSRLYN
SCHEMBL3295665 0.89 IGF1R (0.74) IGF1RTNK2
SCHEMBL3302800 0.89 IGF1R (0.72) IGF1RTNK2
SCHEMBL3297337 0.89 IGF1R (0.72) IGF1RTNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7741324-B2 Imidazotriazines as protein kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2010-06-22 US claimed
EP-1781660-A1 IMIDAZOPYRAZINE AS TYROSINE KINASE INHIBITORS OSI Pharmaceuticals, Inc. (US) 2007-05-09 EP claimed
WO-2006012422-A1 IMIDAZOPYRAZINE AS TYROSINE KINASE INHIBITORS OSI PHARMACEUTICALS, INC. (US) 2006-02-02 WO claimed
US-20060019957-A1 Imidazotriazines as protein kinase inhibitors OSI PHARMACEUTICALS, INC. 2006-01-26 US claimed
US-7741324-B2 Imidazotriazines as protein kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2010-06-22 US disclosed
US-20060019957-A1 Imidazotriazines as protein kinase inhibitors OSI PHARMACEUTICALS, INC. 2006-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060019957-A1 Imidazotriazines as protein kinase inhibitors IGF1R, IRS1, INSR IGF1R 1/4885ROCK2 1151/4885PRKD3 421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.